

1 **DNA Microarray Genotyping and Virulence and Antimicrobial Resistance Gene Profiling**
2 **of Methicillin-Resistant *Staphylococcus aureus* Bloodstream Isolates from Renal Patients**
3
4 **Sinead McNicholas¹, Anna C. Shore², David C. Coleman², Hilary Humphreys^{1,3}, Deirdre**
5 **Fitzgerald Hughes^{1*}**

6 1. Department of Clinical Microbiology, Education and Research Centre, Royal College of
7 Surgeons in Ireland, Beaumont Hospital, Dublin 9, Ireland.

8 2. Microbiology Research Unit, Division of Oral Biosciences, Dublin Dental University
9 Hospital, University of Dublin, Trinity College Dublin, Lincoln Place, Dublin 2, Ireland.

10 3. Department of Microbiology, Beaumont Hospital, Dublin 9, Ireland

11

12

13

14 **Running title: Characterization of MRSA from Renal Patients**

15

16

17 ***Corresponding Author**

18 Dr. Deirdre Fitzgerald Hughes, Department of Clinical Microbiology, RCSI Education and
19 Research Centre, Smurfit Building, Beaumont Hospital, Dublin 9, Ireland. Tel. +353 1 8093711,
20 Fax +353 1 8093709, Email dfitzgeraldhughes@rcsi.ie

21

22

23 **Abstract**

24 Thirty-six methicillin-resistant *Staphylococcus aureus* (MRSA) bloodstream isolates from renal
25 patients were genetically characterized by DNA microarray analysis and *spa* typing. The isolates
26 were highly clonal, belonging mainly to ST22-MRSA-IV. The immune evasion and enterotoxin
27 gene clusters were found in 29/36 (80%) and 33/36 (92%) of isolates, respectively.

28

29

30 *Staphylococcus aureus* is a frequent cause of bloodstream infections (BSI) worldwide (2,
31 3, 17). Methicillin-resistant *Staphylococcus aureus* (MRSA) accounted for 20-50% of *S. aureus*
32 BSIs in our hospital over the past five years (7). Renal patients are at greater risk of MRSA BSI
33 due to impaired immune function, regular contact with healthcare facilities and the presence of
34 central venous catheters (CVCs). We investigated the virulence gene profiles of MRSA BSI
35 isolates from renal patients by DNA microarray analysis. The study was carried out in Beaumont
36 Hospital, Dublin, Ireland, a 820-bed tertiary referral centre harboring the national referral centre
37 for renal and pancreatic transplantation, responsible for approximately 200 hemodialysis patients
38 at any given time. Many studies have investigated the sources and outcomes of *S. aureus*
39 bacteremia among renal patients, however this is the first study, to our knowledge, to genetically
40 characterize MRSA BSI isolates from renal patients (4, 8, 10).

41 MRSA BSI isolates from renal patients were prospectively collected from 2005-2009.
42 Patient details were collected from EARS-Net data and review of their medical notes. Genomic
43 DNA was extracted using a DNeasy® blood and tissue kit (Qiagen, Crawley, UK). *Spa* typing,
44 which involves PCR amplification and sequencing of the polymorphic 24 base pair variable
45 number tandem repeat region within the 3' end of the protein A gene *spa*, was carried out
46 according to the SeqNet website (<http://www.seqnet.org>). Sequencing was performed by
47 Beckman Coulter Genomics (Takeley, UK) and Source BioScience (Dublin, Ireland). Genetic
48 characterization of isolates was undertaken using the StaphyType Kit (Alere Technologies
49 Germany) as previously described (12, 13). The StaphyType Kit is a DNA microarray system
50 that detects 334 *S. aureus* gene sequences including those encoding (i) species markers (*nuc*, *spa*,
51 *coa*, *femA*, *gapA*, *sbi* and *sarA*), (ii) antimicrobial resistance genes (e.g. genes encoding
52 resistance to β -lactams, macrolides, tetracyclines, lincosamides, streptogramins, aminoglycosides

53 and glycopeptides), (iii) genes encoding staphylococcal enterotoxins, toxic shock toxin,
 54 exfoliative toxins, Pantan-Valentine leukocidin, the immune evasion complex (IEC) (*sak*, *chp*,
 55 *scn*, *sea* and *selp*) and the arginine catabolic mobile element (ACME), (iv) microbial surface
 56 components recognizing adhesive matrix molecules (MSCRAMMs), adhesion and biofilm genes
 57 (e.g. *icaA*, *C* and *D*, *cna*, *fnbA*, *fnbB*, *map*, *cna*, *ebh*, *bbp*), (v) SCC and SCC*mec*-associated
 58 genes and sequences and (vi) capsule (types 1, 5 and 8) and *agr* (types I-IV) typing markers (13).
 59 The DNA microarray can also assign *S. aureus* isolates to multilocus sequence types and/or
 60 clonal complexes (CCs) (14).

61 Thirty-six MRSA BSI isolates recovered from renal patients (19 female, 17 male) were
 62 investigated. The median age was 68 and 28 patients (78%) were on hemodialysis. The sources
 63 of BSI are listed in Table 1. For the majority of patients (26/36; 72.2 %), a CVC was the source
 64 of BSI. Six patients (16.7 %) developed a secondary focus of infection and these are listed in
 65 Table 1. The majority of isolates belonged to ST22-MRSA-IV (27/36, 75%) consisting of nine
 66 *spa* types with t032 predominating (12/27, 44.4%) (Table 2). Five isolates (5/36, 13.9%) were
 67 ST5-MRSA-II and *spa* type t463, three (3/36, 8.3%) were ST8, *spa* type t190 and harbored
 68 SCC*mec* IIE & *ccrAB4* or a possible novel SCC*mec* II subtype and one isolate belonged to
 69 ST30-MRSA-IV and *spa*-type t1662.

70 All MRSA BSI isolates from renal patients recovered since 2008 belonged to ST22-
 71 MRSA-IV whereas in the previous three years, 81% belonged to ST22-MRSA-IV with the
 72 remainder consisting of several minor clones (Table 2). ST22-MRSA-IV is the predominant
 73 clone in Irish hospitals, accounting for 85% of MRSA BSI isolates in Ireland in 2009 (15). The
 74 enterotoxin gene cluster *egc* (*seg*, *sei*, *sem*, *sen*, *seo*, *seu*) was found in all isolates except ST8

(33/36, 92 %) isolates. The toxic-shock-toxin (*tst*) gene was found in all ST5-MRSA-II and ST30-MRSA-IV isolates. The gene combination *tst*, *sea*, *sed*, *sej* and *ser*, was exclusive to ST5-MRSA-II isolates and this ST carried more enterotoxin genes than the others. The *sec/sel* cluster was present in a 16/27 (59.3%) ST22-MRSA-IV isolates but in no other STs. The IEC genes are important virulence factors of *S. aureus* (18). An IEC variant was detected in 80% of isolates (29/36) including 22/27 (81%) ST22-MRSA-IV, 1/3 (33.3%) ST8 and all ST5-MRSA-II and ST30-MRSA-IV isolates (Table 2).

We sought to determine the relationship between the genetic characteristics of the infecting isolate and the type of infection, infection complications, or clinical outcome. MRSA BSI with a ST22-MRSA-IV isolate was a cause of death in one patient. In six patients who developed a secondary focus of infection, the infecting isolates belonged to ST22-MRSA-IV (4/6, 66.6%) and ST5-MRSA-II (2/6, 33.3%). Development of a secondary focus of infection was not significantly associated with any particular ST, however the highest rate of secondary infections involved ST5-MRSA-II (2/5 isolates, 40%) compared to ST22-MRSA-IV (4/27 isolates, 15%). This clone carried the most enterotoxin genes including *sea* and has been shown to be significantly associated with more severe *S. aureus* infection (1, 5, 6). Interestingly, the ST5-MRSA-II isolates harbored more antimicrobial resistance genes than ST22-MRSA-IV, but ST8 isolates harbored the greatest number of resistance genes (Table 2). The antibiotic resistant genes *fosB* and *tetE* were present in ST5-MRSA-II, ST8 and ST30 isolates. While nine of the MSCRAMM, adhesion and biofilm genes investigated were detected in all isolates, only ST22-MRSA-IV and ST30-MRSA-IV isolates harbored the collagen binding adhesin gene *cna* and lacked the genes encoding the fibrinogen binding protein *fib* and fibronectin binding protein *fnbB*.

97 (Table 2). ST22-MRSA-IV isolates also lacked the extracellular matrix binding protein *ebh*
98 (Table 2).

99 Recent characterization of other *S. aureus* isolate collections indicates a strong clonal
100 association of virulence genes including the *egc* cluster and IEC variants (11, 16) and these
101 correlations were also evident in the present study. The correlation between carriage of specific
102 virulence genes and clinical outcome remains unclear because host factors are also involved. For
103 example, there is evidence for negative or positive correlation between *egc* gene carriage and
104 infection severity in different isolate collections (5, 9) but how these genes limit or contribute to
105 clinical complications is difficult to establish. Virulence gene expression may also affect the
106 clinical outcome but it is technically challenging to reliably determine gene expression that
107 reflects the *in vivo* setting. The detailed characterization of virulence genes described here
108 supports the clonal distribution of virulence-associated genes in a specific patient group with
109 increased risk for multiple episodes of *S. aureus* infection. Although the small sample size
110 excludes a statistically robust evaluation of the relationship between virulence gene carriage and
111 clinical outcome, carriage of *egc* genes at least, is apparently independent of the development of
112 clinical complications in these patients.

113 In conclusion, this is the first report of MRSA BSI isolates in renal patients that have
114 been typed and characterized in detail using DNA microarray. DNA microarray analysis is a
115 useful, rapid and convenient tool for more comprehensive analysis of virulence and antimicrobial
116 resistance genes in *S. aureus*.

117

118 **References**

- 119 1. **Dauwalder, O., D. Thomas, T. Ferry, A. L. Debard, C. Badiou, F. Vandenesch, J. Etienne,**
120 **G. Lina, and G. Monneret.** 2006. Comparative inflammatory properties of staphylococcal
121 superantigenic enterotoxins SEA and SEG: implications for septic shock. *J Leukoc Biol* **80**:753-
122 8.
- 123 2. **Diekema, D. J., S. E. Beekmann, K. C. Chapin, K. A. Morel, E. Munson, and G. V. Doern.**
124 2003. Epidemiology and outcome of nosocomial and community-onset bloodstream infection. *J*
125 *Clin Microbiol* **41**:3655-60.
- 126 3. **Diekema, D. J., M. A. Pfaller, F. J. Schmitz, J. Smayevsky, J. Bell, R. N. Jones, and M.**
127 **Beach.** 2001. Survey of infections due to *Staphylococcus* species: frequency of occurrence and
128 antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America,
129 Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program,
130 1997-1999. *Clin Infect Dis* **32 Suppl 2**:S114-32.
- 131 4. **Engemann, J. J., J. Y. Friedman, S. D. Reed, R. I. Griffiths, L. A. Szczech, K. S. Kaye, M. E.**
132 **Stryjewski, L. B. Reller, K. A. Schulman, G. R. Corey, and V. G. Fowler, Jr.** 2005. Clinical
133 outcomes and costs due to *Staphylococcus aureus* bacteremia among patients receiving long-term
134 hemodialysis. *Infect Control Hosp Epidemiol* **26**:534-9.
- 135 5. **Ferry, T., D. Thomas, A. L. Genestier, M. Bes, G. Lina, F. Vandenesch, and J. Etienne.**
136 2005. Comparative prevalence of superantigen genes in *Staphylococcus aureus* isolates causing
137 sepsis with and without septic shock. *Clin Infect Dis* **41**:771-7.
- 138 6. **Fowler, V. G., Jr., C. L. Nelson, L. M. McIntyre, B. N. Kreiswirth, A. Monk, G. L. Archer,**
139 **J. Federspiel, S. Naidich, B. Remortel, T. Rude, P. Brown, L. B. Reller, G. R. Corey, and S.**
140 **R. Gill.** 2007. Potential associations between hematogenous complications and bacterial genotype
141 in *Staphylococcus aureus* infection. *J Infect Dis* **196**:738-47.

- 142 7. **Health, Protection, Surveillance, and Centre.** 2010. Enhanced EARS-net surveillance report
 143 for 2010. report. [http://www.hpsc.ie/hpsc/A-](http://www.hpsc.ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/EuropeanAntimicrobialResistanceSurveillanceSystemEARSS/EnhancedBacteraemiaSurveillance/PublicationsandPresentations/File,2291,en.pdf)
 144 [Z/MicrobiologyAntimicrobialResistance/EuropeanAntimicrobialResistanceSyst](http://www.hpsc.ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/EuropeanAntimicrobialResistanceSurveillanceSystemEARSS/EnhancedBacteraemiaSurveillance/PublicationsandPresentations/File,2291,en.pdf)
 145 [emEARSS/EnhancedBacteraemiaSurveillance/PublicationsandPresentations/File,2291,en.p](http://www.hpsc.ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/EuropeanAntimicrobialResistanceSurveillanceSystemEARSS/EnhancedBacteraemiaSurveillance/PublicationsandPresentations/File,2291,en.pdf)
 146 [df](http://www.hpsc.ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/EuropeanAntimicrobialResistanceSurveillanceSystemEARSS/EnhancedBacteraemiaSurveillance/PublicationsandPresentations/File,2291,en.pdf).
- 147 8. **Inrig, J. K., S. D. Reed, L. A. Szczech, J. J. Engemann, J. Y. Friedman, G. R. Corey, K. A.**
 148 **Schulman, L. B. Reller, and V. G. Fowler, Jr.** 2006. Relationship between clinical outcomes
 149 and vascular access type among hemodialysis patients with *Staphylococcus aureus* bacteremia.
 150 Clin J Am Soc Nephrol 1:518-24.
- 151 9. **Lalani, T., J. J. Federspiel, H. W. Boucher, T. H. Rude, I. G. Bae, M. J. Rybak, G. T.**
 152 **Tonthat, G. R. Corey, M. E. Stryjewski, G. Sakoulas, V. H. Chu, J. Alder, J. N.**
 153 **Steenbergen, S. A. Luperchio, M. Campion, C. W. Woods, and V. G. Fowler.** 2008.
 154 Associations between the genotypes of *Staphylococcus aureus* bloodstream isolates and clinical
 155 characteristics and outcomes of bacteremic patients. J Clin Microbiol 46:2890-6.
- 156 10. **Li, Y., J. Y. Friedman, B. F. O'Neal, M. J. Hohenboken, R. I. Griffiths, M. E. Stryjewski, J.**
 157 **P. Middleton, K. A. Schulman, J. K. Inrig, V. G. Fowler, Jr., and S. D. Reed.** 2009.
 158 Outcomes of *Staphylococcus aureus* infection in hemodialysis-dependent patients. Clin J Am Soc
 159 Nephrol 4:428-34.
- 160 11. **Monecke, S., G. Coombs, A. C. Shore, D. C. Coleman, P. Akpaka, M. Borg, H. Chow, M. Ip,**
 161 **L. Jatzwauk, D. Jonas, K. Kadlec, A. Kearns, F. Laurent, F. G. O'Brien, J. Pearson, A.**
 162 **Ruppelt, S. Schwarz, E. Scicluna, P. Slickers, H. L. Tan, S. Weber, and R. Ehricht.** A field
 163 guide to pandemic, epidemic and sporadic clones of methicillin-resistant *Staphylococcus aureus*.
 164 PLoS One 6:e17936.

- 165 12. **Monecke, S., and R. Ehricht.** 2005. Rapid genotyping of methicillin-resistant *Staphylococcus*
166 *aureus* (MRSA) isolates using miniaturised oligonucleotide arrays. Clin Microbiol Infect **11**:825-
167 33.
- 168 13. **Monecke, S., L. Jatzwauk, S. Weber, P. Slickers, and R. Ehricht.** 2008. DNA microarray-
169 based genotyping of methicillin-resistant *Staphylococcus aureus* strains from Eastern Saxony.
170 Clin Microbiol Infect **14**:534-45.
- 171 14. **Monecke, S., P. Slickers, and R. Ehricht.** 2008. Assignment of *Staphylococcus aureus* isolates
172 to clonal complexes based on microarray analysis and pattern recognition. FEMS Immunol Med
173 Microbiol **53**:237-51.
- 174 15. **O'Connell, B., A. Rossney, and H. Barry.** 2009. National Methicillin-Resistant *Staphylococcus*
175 *aureus* Reference Laboratory Annual Report, [http://www.stjames.ie/Departments/DepartmentsA-](http://www.stjames.ie/Departments/DepartmentsA-Z/N/NationalMRSAResearchLaboratory/DepartmentinDepth/AnnRpt2009.pdf)
176 [Z/N/NationalMRSAResearchLaboratory/DepartmentinDepth/AnnRpt2009.pdf](http://www.stjames.ie/Departments/DepartmentsA-Z/N/NationalMRSAResearchLaboratory/DepartmentinDepth/AnnRpt2009.pdf).
- 177 16. **van Belkum, A., D. C. Melles, S. V. Snijders, W. B. van Leeuwen, H. F. Wertheim, J. L.**
178 **Nouwen, H. A. Verbrugh, and J. Etienne.** 2006. Clonal distribution and differential occurrence
179 of the enterotoxin gene cluster, egc, in carriage- versus bacteremia-associated isolates of
180 *Staphylococcus aureus*. J Clin Microbiol **44**:1555-7.
- 181 17. **van der Mee-Marquet, N., A. S. Domelier, N. Girard, and R. Quentin.** 2004. Epidemiology
182 and typing of *Staphylococcus aureus* strains isolated from bloodstream infections. J Clin
183 Microbiol **42**:5650-7.
- 184 18. **van Wamel, W. J., S. H. Rooijackers, M. Ruyken, K. P. van Kessel, and J. A. van Strijp.**
185 2006. The innate immune modulators staphylococcal complement inhibitor and chemotaxis
186 inhibitory protein of *Staphylococcus aureus* are located on beta-hemolysin-converting
187 bacteriophages. J Bacteriol **188**:1310-5.

188

189

TABLE 1. Infection types found in renal patients with MRSA bloodstream infections (BSIs) in the present study

Infection type	Number of isolates (%)
Source of BSI	
Central venous catheter	26 (72.2)
Skin and soft tissue infection	2 (5.6)
Infected peripheral vascular catheter	2 (5.6)
Infective endocarditis	1 (2.8)
Surgical site infection	1 (2.8)
Intra-abdominal infection	1 (2.8)
Not identified	3 (8.3)
Secondary foci of infection	
Osteomyelitis	1 (2.8)
Infective endocarditis	3 (8.3)
Implantable cardiac rhythm device	2 (5.6)

1 **TABLE 2. Molecular characteristics of 36 MRSA bloodstream isolates from renal patients**
 2 **recovered between 2005 and 2009**

ST	SCCmec type (n)	<i>spa</i> types (n)	<i>agr</i> /capsule type	Antimicrobial resistance genes ^a	Virulence-associated genes ^a	MSCRAMM, adhesion & biofilm genes ^a
ST22	IV (27)	t025(1), t032(12), t515(3), t557(3), t1214(3), t2945(2), t3185(1), t5420(1), t7636(1)	I/5	<i>erm</i> (C) (21), <i>lnu</i> (A)/ <i>aacA-aphD/aadD/mupA</i> (1)	<i>seb</i> (2), <i>sec/l</i> (16), <i>egc</i> , <i>sak/chp/scn</i> (22; IEC type B), ACME (1)	<i>bbp</i> (25), <i>cna</i> , <i>map</i> , <i>sdrC</i> , <i>sdrD</i> (26), <i>sasG</i>
ST5	II (5)	t463 (5)	II/5	<i>erm</i> (A), <i>aadD</i> , <i>tetefflux</i> , <i>fosB</i> , <i>merA</i> & <i>merB</i> (1)	<i>tst</i> , <i>sed/j/r</i> , <i>egc</i> , <i>sea/sak/chp/scn</i> (IEC type A)	<i>bbp</i> , <i>ebh</i> , <i>fib</i> , <i>fnbB</i> , <i>map</i> , <i>sdrC</i> , <i>sdrD</i> , <i>sasG</i>
ST8	IIE & <i>ccrAB4</i> (2) Novel II subtype (1) ^b	t190 (3)	I/5	<i>erm</i> (A), <i>tetefflux</i> , <i>fosB</i> , <i>qacA</i> , <i>aacA-aphD</i> , <i>aadD/aphA3-sat</i> (2), <i>merA</i> & <i>merB</i> (2)	<i>sea/sak/scn</i> (IEC type D)	<i>bbp</i> , <i>ebh</i> , <i>fib</i> , <i>fnbB</i> (2), <i>map</i> (2), <i>sdrD</i>
ST30	IV (1)	t1662 (1)	III/8	Q6GD50 (<i>fusC</i>), <i>tetefflux</i> , <i>fosB</i>	<i>tst</i> , <i>egc</i> , <i>sak/chp/scn</i> (IEC type B)	<i>bbp</i> , <i>cna</i> , <i>ebh</i> , <i>fib</i> , <i>map</i> , <i>sdrC</i> , <i>sdrD</i>

3 ^a The number of positive isolates are indicated in parenthesis if not all isolates within a genotype
 4 were positive for the gene indicated. All isolates harbored the beta-lactamase resistance gene
 5 *blaZ* and the MSCRAMM, adhesion and biofilm genes *icaA*, *icaC* & *icaD*, *clfA* & *clfB*, *ebpS*,
 6 *eno*, *fnbA* and *vwb*.

7 ^bPossible novel SCCmec II subtype identified in one ST8 MRSA isolate that yielded signals for
 8 class A *mec* complex, *ccrAB2* but lacked signals for *kdp* and *aadD* (pUB110).

9
 10